



MAIL STOP PATENT
Attorney Docket No. 25352

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SCHRACHT, et al.

Serial No. 10/627,990

Filed: July 28, 2003

Title: **IMPROVED TRANSDERMAL DELIVERY SYSTEM**

TRANSMITTAL LETTER

The Commissioner for Patents
Alexandria, Virginia 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Information Disclosure Statement
- (3) Form PTO-1449 with fourteen (14) references
- (4) Copy of European Search Report

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:



Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529

Date: October 8, 2003

NATH & ASSOCIATES PLLC
1030 15th Street, NW - 6th Floor
Washington, D.C. 20005
GMN/TLJ/lst:IDS.trans



OCT 08 2003

MAIL STOP PATENT
Attorney Docket No. 25352

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SCHRACHT, et al.

Serial No. 10/627,990

Filed: July 28, 2003

Title: IMPROVED TRANSDERMAL DELIVERY SYSTEM

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Alexandria, Virginia 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

[x] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

[] i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or

[] ii. a check in the amount required by 37 C.F.R. §1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by §1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
or

[] Appropriate certification is attached.

[x] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.


[x] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: 

Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529

Date: October 8, 2003

NATH & ASSOCIATES PLLC

1030 15th Street, N.W., 6th Floor

Washington, D.C. 20005

Tel. (202) 775-8383

Fax. (202) 775-8396

GMN/TLJ/las (IDS.revisedTLJ04.08.02)



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket 25352	Serial No. 10/627,990
Applicant SCHRACHT, et al.	
Filing Date July 28, 2003	Group Art Unit Not yet assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,601,839	Feb. 11, 1997	Quan et al.			Apr. 26, 1995
	AB	5,834,010	Nov. 10, 1998	Quan et al.			Jan. 3, 1997
	AC	6,620,429 (Counterpart to DE 198 14 083)	Sep. 16, 2003	Müller			July 30, 2001

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AD	WO 99/49852	Oct. 7, 1999	WIPO			Abstract
	AE	1 256 340	Nov. 13, 2002	EP			N/A
	AF	WO 02/074286	Sept. 26, 2002	WIPO			N/A
	AG	WO 02/26217	Apr. 4, 2002	WIPO			N/A
	AH	WO 98/00126	Jan. 8, 1998	WIPO			N/A
	AI	WO 94/07468	Apr. 14, 1994	WIPO			N/A
	AJ	2 792 529	Oct. 27, 2000	FR			Abstract
	AK	100 60 550	Apr. 18, 2002	DE			Abstract
	AL	198 14 083	Oct. 14, 1999	DE			No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AM	Roy, Samir D., et al., "Transdermal Delivery of Narcotic Analgesics: pH, Anatomical, and Subject Influences on Cutaneous Permeability of Fentanyl and Sufentanil". Pharmaceutical Research, Vol. 7, No. 8, pp. 842-847, 1990.
AN	Roy, Samir D., et al., "Controlled Transdermal Delivery of Fentanyl: Characterization of Pressure-Sensative Adhesives for Matrix Patch Design". Journal of Pharmaceutical Sciences, Vol. 85, No. 5, pp. 491-495, May 1996.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.